WATERTOWN, Mass. — January 6, 2026 — Leads & Copy — Remix Therapeutics (Remix), a clinical-stage biotechnology company focused on developing small molecule therapies that modulate RNA processing, has appointed Mythili Koneru, MD, PhD, as Chief Medical Officer.
Dr. Koneru will oversee clinical development, medical strategy, and regulatory engagement as the company advances its pipeline. This includes REM-422, a first-in-class oral small molecule mRNA degrader, through clinical development and regulatory milestones.
Pete Smith, PhD, Co-Founder and Chief Executive Officer of Remix, stated that Dr. Koneru’s experience in advancing novel oncology therapies through translational science and clinical execution will be critical as they advance REM-422 and their broader pipeline. He added that they are excited to have her lead their development group as they translate their RNA-targeting platform into medicines for patients.
Dr. Koneru brings extensive experience in drug development, with a history of advancing therapeutics from early development through later-stage clinical programs. She succeeds Chris Bowden, MD, who retired as Chief Medical Officer at the end of 2025.
Dr. Koneru said she was drawn to Remix by the opportunity to build on the clinical data for REM-422 in adenoid cystic carcinoma and help translate that progress for patients. She added that Remix’s REMaster™ platform offers the potential to address unmet medical needs in targets previously considered intractable. Dr. Koneru said she looks forward to working with the team to design clinical programs that bring REM-422 and the broader pipeline to patients in need.
Most recently, Dr. Koneru served as Chief Medical Officer at Legend Biotech, where she oversaw clinical development and medical affairs activities. Prior to that, she was the Chief Medical Officer of Marker Therapeutics, leading development of cellular therapies and peptide vaccines in its immune-oncology portfolio. She also designed early-stage clinical trials for hematologic malignancies and solid tumors as Associate Vice President of Immuno-Oncology at Eli Lilly. Dr. Koneru also served as Senior Medical Director of Early Phase Clinical Development at Eli Lilly. Before joining Eli Lilly, Dr. Koneru was an oncology fellow at Memorial Sloan-Kettering Cancer Center, developing adoptive T cell therapies for leukemia and solid tumors in early phase clinical trials. She earned her bachelor’s degree in biology from the University of Chicago, her doctorate degree in Biomedical Engineering from New York University, and her medical degree from Robert Wood Johnson Medical School.
REM-422 is described as a first-in-class, potent, selective, and oral small molecule mRNA degrader that induces the reduction of MYB mRNA and subsequent protein expression. It functions by facilitating the incorporation of a poison exon in the MYB mRNA transcript, leading to nonsense-mediated decay of the transcript. REM-422 is currently in Phase 1 clinical studies for Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS). The U.S Food and Drug Administration has granted REM-422 Orphan Drug Designation for ACC and AML.
Remix Therapeutics is a clinical-stage biotechnology company developing small molecule therapies designed to reprogram RNA processing and address disease drivers. The company’s REMaster™ technology platform leverages data science, biomolecular sciences and chemistry to identify orally administered compounds that modulate gene expression. Remix’s therapeutic approach led to the discovery of REM-422, an RNA processing modulator in oncology, currently in Phase 1 clinical studies to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR-MDS) and adenoid cystic carcinoma (ACC).
Media Contact:
Lisa Buffington
Buffington Comms
lbuffington@remixtx.com
Investor Contact:
Will O’Connor
Precision AQ
Will.OConnor@precisionaq.com
Source: Remix Therapeutics
